I came across a transcript of an interview with Yehuda Handelsman, former President of American College of Endocrinology. It is evident that he is not a native speaker of English, but I found the transcript to be well worth reading. http://www.diabetesincontrol.com/yehuda-handelsman-transcript/
He comes across as sensible and well-versed in the current research results concerning LDL targets. It turns out that they’ve introduced a new category of “extreme risk” for which the LDL target should be lowered to 55 because the research shows this gets a significant improvement in outcomes and it can be achieved without excessive side-effects via some of the newest medicines. He also touches on A1C targets and how quickly to get there, the utility of CGM for T2, and the promise of closed-loop systems.